Brief: Morphosys Says Receives U.S. FDA Fast Track Designation For Tulmimetostat In Endometrial Cancer
12/09/2023 21:56
Sept 12 (Reuters) - MorphoSys AG MORG.DE :
* MORPHOSYS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR
TULMIMETOSTAT IN ENDOMETRIAL CANCER
Source text for Eikon: ID:nEQ1g3kCda
Further company coverage: MORG.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Morphosys AG
See all newsBrief: Morphosys Announces Voluntary Delisting From The Nasdaq Global Market
Brief: Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00
Brief: Morphosys And Novartis Sign Delisting Agreement
Brief: Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders
Brief: Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO